Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00156299 | Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate | terminated | Phase 1 | 15 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 19, 2013 | clinicaltrials |
| NCT01239485 | Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents | unknown | Phase 1 | 18 | Seoul National University HospitalOTHER | 1 | Nov 19, 2013 |
| clinicaltrials |
| NCT00722488 | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma | completed | Phase 1 | 56 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT01983761 | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | unknown | Phase 1 / Phase 2 | 25 | Targazyme, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT01823718 | Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes | unknown | Phase 1 | 18 | Nantes University HospitalOTHER | 1 | Nov 15, 2013 | clinicaltrials |
| NCT00462787 | Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2013 | clinicaltrials |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Nov 6, 2013 | clinicaltrials |
| NCT00985530 | Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | terminated | Phase 1 | 4 | Northwestern UniversityOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00096018 | Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 43 | Roswell Park Cancer InstituteOTHER | 1 | Oct 24, 2013 | clinicaltrials |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects | completed | Phase 1 | 186 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Oct 22, 2013 | clinicaltrials |
| NCT00003356 | Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma | completed | Phase 1 / Phase 2 | 58 | University of RochesterOTHER | 1 | Oct 16, 2013 | clinicaltrials |
| NCT00258271 | Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 18 | University of RochesterOTHER | 1 | Oct 16, 2013 | clinicaltrials |
| NCT00016016 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00890500 | Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | completed | Phase 1 | 12 | Fate TherapeuticsINDUSTRY | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00049582 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00068315 | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00079378 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00098423 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00293345 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301938 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00331513 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00398515 | Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00470197 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00612612 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | terminated | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01185262 | Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia(LLC-LENAR-08) | completed | Phase 1 | 25 | MD Anderson International Spain SAOTHER | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00004858 | Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | Parker Hughes Cancer CenterOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00009776 | Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | University of California, DavisOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00023816 | Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma | unknown | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 0 | Sep 20, 2013 | clinicaltrials |
| NCT00031902 | Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | Lymphoma Trials OfficeOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00032149 | Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Lymphoma Trials OfficeOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00363090 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 84 | Toronto Sunnybrook Regional Cancer CentreOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00547365 | Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction | completed | Phase 1 / Phase 2 | 10 | University of TennesseeOTHER | 1 | Sep 19, 2013 | clinicaltrials |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00405743 | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | completed | Phase 1 / Phase 2 | 153 | Clavis PharmaINDUSTRY | 6 | Sep 18, 2013 | clinicaltrials |
| NCT00807872 | Radioimmunoimaging of AL Amyloidosis | completed | Phase 1 | 40 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT01815086 | Radioimmunoimaging of Light Chain (AL) Amyloidosis | completed | Phase 1 | 30 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00028847 | Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 60 | Commissie Voor Klinisch Toegepast OnderzoekOTHER | 2 | Sep 17, 2013 | clinicaltrials |
| NCT00176475 | Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | terminated | Phase 1 | 2 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00324597 | AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | unknown | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00544999 | Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia | unknown | Phase 1 | 21 | Institut de Recherche Clinique sur les Cancers et le SangOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00996359 | Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation | terminated | Phase 1 | 4 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00046488 | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 70 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT00048555 | Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 90 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT01701375 | A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 9, 2013 | clinicaltrials |
| NCT00738829 | Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL | completed | Phase 1 / Phase 2 | 45 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Aug 30, 2013 | clinicaltrials |
| NCT00457574 | Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas | withdrawn | Phase 1 | 0 | Gemin XINDUSTRY | 0 | Aug 28, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Nov 19, 2013source: clinicaltrials